ELTX

Elicio TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$7.00

+130.3% vs current

Most likely

Base case

45%

Probability

Target price

$2.80

-7.9% vs current

B-

Bear case

30%

Probability

Target price

$1.20

-60.5% vs current

AI sentiment snapshot

Latest data as of 2026-06-16

AI commentary

Sentiment is negative and headline intensity is high because the June 15 company release turned a long-telegraphed mid-2026 readout into a thesis break. Trusted coverage indicated ELTX fell sharply on June 15 after the primary-endpoint miss. The repaired catalyst set now separates near-term financing risk from the longer-horizon need to secure funding or partnership support for any R0-selected Phase 3 program, but thin analyst-revision visibility and post-hoc dependence still argue for cautious monitoring rather than a confident rebound call.

RankAlpha Sentiment Codex - 2026-06-16

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30catalystFinancing or partnering decision after the Phase 2 missHigh impact

After reporting that AMPLIFY-7P missed its primary endpoint, Elicio said it is evaluating multiple strategic financing and partnering opportunities, while the May Q1 update said cash runway extends only into Q4 2026; that keeps near-term dilution or structured-deal risk high even after the selloff. [#8-K-2026-06-15] [#PR-EARNINGS-2026-05-12]

2026-10-31eventRegulatory feedback on the narrowed Phase 3 pathHigh impact

The June 15 company filing says Elicio issued a release with randomized Phase 2 AMPLIFY-7P results and a refined Phase 3 development strategy for ELI-002 7P; the fetched exhibit stated the study did not meet the intent-to-treat primary DFS endpoint but highlighted post-hoc R0 subgroup and immune-response signals. FDA alignment is now the key event for whether the program remains registrationally credible. [#8-K-2026-06-15]

2027-06-30catalystPhase 3 funding, partner support, and trial-start path for R0-selected ELI-002 7PHigh impact

The distinct long-horizon question is whether Elicio can fund or partner a registrational program after a primary-endpoint miss. The June 15 release described a refined Phase 3 strategy focused on R0 resected patients with additional dosing and said the company is evaluating strategic financing and partnering opportunities to support future development, while the May update placed runway only into Q4 2026. [#8-K-2026-06-15] [#PR-EARNINGS-2026-05-12]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-16 • Updated nightlySource: Internal modelMethodology